Lineage Cell Therapeutics (LCTX) Equity Income (2015 - 2024)

Lineage Cell Therapeutics' Equity Income history runs 10 years deep, the most recent figure standing at -$4000.0 for Q2 2024.

• In Q2 2024, Equity Income changed N/A year-over-year to -$4000.0; the TTM figure through Mar 2025 stood at -$4000.0 (up 82.61% YoY), while the FY2024 annual figure was -$4000.0, up 82.61% from the prior year.
• Equity Income for Q2 2024 stood at -$4000.0, up from -$23000.0 in the prior quarter.
• The five-year high for Equity Income was $3.7 million in Q4 2020, with the low at -$4.1 million in Q2 2020.
• The 5-year median for Equity Income is -$375000.0 (2022), against an average of -$494571.4.
• The sharpest annual moves came in 2021 and 2022: Equity Income surged 114.23% in 2021, then slumped 220.17% in 2022.
• Lineage Cell Therapeutics' Equity Income stood at $3.7 million in 2020, then tumbled by 145.29% to -$1.7 million in 2021, then soared by 69.19% to -$517000.0 in 2022, then jumped by 95.55% to -$23000.0 in 2023, then jumped by 82.61% to -$4000.0 in 2024.
• Business Quant data shows LCTX's Equity Income at -$4000.0 in Q2 2024, -$23000.0 in Q3 2023, and $40000.0 in Q1 2023.